Fairmount Funds Management LLC
WEST CONSHOHOCKEN, PA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$1.59B2026 Q3
Positions12
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.97.5%
Fairmount Funds Management LLC reported 12 positions worth $1.59B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: ORKA (19.4%). Biggest move: new buy KRSA ($291.3M).
10 / 12 positions shown
| # | Symbol | Company | Value ↓ | % Port. | Shares | 1Y | YTD | Since reported |
|---|---|---|---|---|---|---|---|---|
| ▸ 1 | ORKA | $308.6M | 19.35% | 3,705,262 | — | — | +19.1% | |
| ▸ 2 | KRSA | $291.3M | 18.27% | 9,103,729 | — | — | — | |
| ▸ 3 | DNTH | $223.4M | 14.01% | 2,537,191 | — | — | +1.7% | |
| ▸ 4 | DMRA | $185.4M | 11.63% | 8,713,000 | — | — | +1.5% | |
| ▸ 5 | COGT | $176.2M | 11.05% | 5,503,418 | — | — | -10.8% | |
| ▸ 6 | VRDN | $104.8M | 6.57% | 5,090,928 | — | — | +49.9% | |
| ▸ 7 | ELVN | $85.1M | 5.33% | 1,855,644 | — | — | +3.9% | |
| ▸ 8 | JBIO | $64.0M | 4.01% | 4,553,494 | — | — | — | |
| ▸ 9 | ZBIO | $64.0M | 4.01% | 2,371,358 | — | — | — | |
| ▸ 10 | CBIO | $52.5M | 3.30% | 3,601,316 | — | — | -3.0% |
Read the 2026-Q2 quarterly report · 13F Filing Calendar
Frequently Asked Questions
What stocks does Fairmount Funds Management LLC hold as of Q3 2026?
Fairmount Funds Management LLC reported 12 positions worth $1.59B in its Q3 2026 13F filing. Largest positions: ORKA (19.4%), KRSA (18.3%), DNTH (14.0%), DMRA (11.6%) and COGT (11.1%).
What did Fairmount Funds Management LLC buy in Q3 2026?
New positions: KRSA and DMRA. Added to: CBIO and ZBIO.
What did Fairmount Funds Management LLC sell in Q3 2026?
Sold out entirely: DAMORA THERAPEUTICS INC and APOGEE THERAPEUTICS INC.
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.